Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis

OBJECTIVE: Erlotinib plus gemcitabine is approved in Japan for the treatment of metastatic pancreatic cancer. The POLARIS surveillance study investigated safety (focusing on interstitial lung disease [ILD]) and efficacy of erlotinib plus gemcitabine in Japanese pancreatic cancer patients. METHODS: P...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Jpn J Clin Oncol
Päätekijät: Furuse, Junji, Gemma, Akihiko, Ichikawa, Wataru, Okusaka, Takuji, Seki, Akihiro, Ishii, Tadashi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2017
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896695/
https://ncbi.nlm.nih.gov/pubmed/28541474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyx075
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia